Karla J. Helbig, Nicholas S. Eyre, Evelyn Yip, Sumudu Narayana, Kui Li, Guillaume Fiches, Erin M. McCartney, Rohit K. Jangra, Stanley M. Lemon, Michael R. Beard – 11 July 2011 – The interferon‐stimulated gene, viperin, has been shown to have antiviral activity against hepatitis C virus (HCV) in the context of the HCV replicon, although the molecular mechanisms responsible are not well understood.

Hamish A. Innes, Sharon J. Hutchinson, Samuel Allen, Diptendu Bhattacharyya, Peter Bramley, Toby E.S. Delahooke, John F. Dillon, Ewan Forrest, Andrew Fraser, Ruth Gillespie, David J. Goldberg, Nicholas Kennedy, Scott McDonald, Allan McLeod, Peter R. Mills, Judith Morris, Peter Hayes, on behalf of the Hepatitis C Clinical Database Monitoring Committee.

Dawn M. Torres, Frances J. Jones, Janet C. Shaw, Christopher D. Williams, John A. Ward, Stephen A. Harrison – 11 July 2011 – Medication combinations that improve the efficacy of thiazolidinediones or ameliorate weight‐gain side effects of therapy represent an attractive potential treatment for (NASH). The aim of this randomized, open‐label trial was to assess the efficacy of rosiglitazone and metformin in combination versus rosiglitazone and losartan, compared to rosiglitazone alone, after 48 weeks of therapy.

Marc G. Ghany, Hae‐Young Kim, Anne Stoddard, Elizabeth C. Wright, Leonard B. Seeff, Anna S.F. Lok, the HALT‐C Trial Group – 11 July 2011 – Predicting clinical outcomes in patients with chronic hepatitis C is challenging. We used the hepatitis C long‐term treatment against cirrhosis (HALT‐C) trial database to develop two models, using baseline values of routinely available laboratory tests together with changes in these values during follow‐up to predict clinical decompensation and liver‐related death/liver transplant in patients with advanced hepatitis C.

Thomas‐Matthias Scherzer, Albert Friedrich Stättermayer, Michael Strasser, Hermann Laferl, Andreas Maieron, Rudolf Stauber, Christian Datz, Emina Dulic‐Lakovic, Petra Steindl‐Munda, Harald Hofer, Peter Ferenci – 11 July 2011 – The IL28B genotype is the most important pretreatment predictor of treatment outcome in patients with chronic hepatitis C.

Li Jiang, Lunan Yan, Bo Li, Tianfu Wen, Jichun Zhao, Lisheng Jiang, Jiayin Yang, Mingqing Xu, Wentao Wang – 11 July 2011

Susana Casas, Laura Muñoz, Raquel Moure, Jose Castellote, Maria R. Guerra, Lucia Gonzalez, Ana Andreu, Antoni G. Rafecas, Fernando Alcaide, Miguel Santin – 11 July 2011 – The ability of interferon‐γ release assays (IGRAs) to detect latent tuberculosis (TB) infection before liver transplantation (LT) is not well established.

Y.‐F. Liaw, J.‐D. Jia, H.L.Y. Chan, K.H. Han, T. Tanwandee, W.L. Chuang, D.M. Tan, X.Y. Chen, E. Gane, T. Piratvisuth, L. Chen, Q. Xie, J.J.Y. Sung, C. Wat, C. Bernaards, Y. Cui, P. Marcellin – 11 July 2011 – As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa‐2a (PEG‐IFNα‐2a) therapy in hepatitis B e antigen (HBeAg)‐positive patients, the efficacy and safety of either 24 or 48 weeks' duration and 90 μg/week or 180 μg/week doses were compared.

Ya‐Li Jia, Lei Shi, Jun‐Nian Zhou, Chun‐Jiang Fu, Lin Chen, Hong‐Feng Yuan, Yun‐Fang Wang, Xin‐Long Yan, Ying‐Chen Xu, Quan Zeng, Wen Yue, Xue‐Tao Pei – 11 July 2011 – The high incidence rate of hepatocellular carcinoma (HCC) is mainly the result of frequent metastasis and tumor recurrence. Unfortunately, the underlying molecular mechanisms driving HCC metastasis are still not fully understood. It has been demonstrated that tumor stroma cells contribute to primary tumor growth and metastasis.

Mary E. Rinella, M. Shaddab Siddiqui, Konstantina Gardikiotes, Jeanne Gottstein, Marc Elias, Richard M. Green – 11 July 2011 – In humans with nonalcoholic fatty liver, diabetes is associated with more advanced disease. We have previously shown that diabetic db/db mice are highly susceptible to methionine choline‐deficient diet (MCD)‐induced hepatic injury.